Potential Role of Fluoroquinolone Therapy in Childhood Otitis Media

Pediatric Infectious Disease Journal

Volumn 23, Issue 5, 2004, Pages 390-398

  Dagan, Ron ^a   Arguedas, Adriano ^b   Schaad, Urs B ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Instituto de Atencion Pediatrica Costa Rica   (Costa Rica)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Antimicrobial resistance; Fluoroquinolones; Gatifloxacin; Otitis media; Pediatrics

Indexed keywords

8 METHOXYFLUOROQUINOLONE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CEFUROXIME AXETIL; CLINDAMYCIN; GATIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHROPATHY; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; HUMAN; MYRINGOTOMY; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 2442607457     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000126272.08795.7a     Document Type: Review

References (60)

1. Dagan R, Givon-Lavi N, Shkolnik L, Yagupsky P, Fraser D. Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: implication for immunizing with conjugate vaccines. J Infect Dis. 2000;181:1322-1329.
2. Johnson CE, Belman S. The role of antibacterial therapy of acute otitis media in promoting drug resistance. Paediatr Drugs, 2001;3:639-647.
3. Randall DA, Fornadley JA, Kennedy KS. Management of recurrent otitis media, Am Fam Physician. 1992;45:2117-2123.
4. Pichichero ME. Recurrent and persistent otitis media. Pediatr Infect Dis J. 2000;19:911-916.
5. Leibovitz E, Dagan R, Antibiotic treatment for acute otitis media, Int J Antimicrob Agents. 2000;15:169-177.
6. Klein J. Otitis externa, otitis media, and mastoiditis, In: Mandell GL, et al., eds, Principles and Practice of Infectious Diseases. 5th ed, New York, NY: Churchill Livingstone; 2000:669-75.
7. Carlin SA, Marchant CD, Shurin PA, et al. Host factors and early therapeutic response in acute otitis media. J Pediatr. 1991;118:178-183.
8. Dagan R, Leibovitz Greenberg D, et al. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcomes. Pediatr Infect Dis J. 1998;17:776-782.
9. Abzug MJ. Meeting the challenge of antibiotic resistance: an evidence-based approach to treatment. Pediatr Annu. 1999;28:460-467.
10. Dagan R. Clinical significance of resistant organisms in otitis media. Pediatr Infect Dis J. 2000;19:378-382.
11. Jacobs MR, Dagan R, Appelbaum PC, Burch DJ. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrob Agents Chemother. 1998;42:589-595.
12. Babin E, Lemarchand V, Moreau S, et al. Failure of antibiotic therapy in acute otitis media. J Laryngol Otol. 2003;117:173-176.
13. Piglansky L, Leibovitz E, Raiz S, et al. Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatr Infect Dis J. 2003;22:404-412.
14. Garau J, Barry B, Butzler JP, Dagan R, Pelton SI. Upper respiratory tract infections: etiology, current treatment, and experience with fluoroquinolones. Clin Microbiol Infect. 1998;4(suppl 2):S51-S58.
15. Dagan R, Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect Dis. 2002;2:593-604.
16. Jacobs MR, Bajaksouzian S, Zilles A, et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study. Antimicrob Agents Chemother. 1999;43:1901-1908.
17. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother. 2001;45:1721-1729.
18. Dagan R, Greenberg D, Jacobs MR. Pneumococcal infections. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2004:1204-1258.
19. Arguedas A, Loaiza C, Perez A, et al. Microbiology of acute otitis media in Costa Rican children. Pediatr Infect Dis J. 1998;17:680-684.
20. Arguedas A, Dagan R, Soley C, et al. Microbiology of otitis media in Costa Rican children, 1999 through 2001. Pediatr Infect Dis J. 2003;22:1063-1068.
21. Dowell SF, Butler JC, Giebink S, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 1999;18:1-9.
22. Whitney CG. The potential of pneumococcal conjugate vaccines in children. Pediatr Infect Dis J. 2002;21:961-970.
23. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
24. Russell F, Mulholland K. Prevention of otitis media by vaccination. Drugs. 2002;62:1441-1445.
25. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J. 2001;20:829-837.
26. Pichichero ME, McLinn S, Aronovitz G, et al. Cefprozil treatment of persistent and recurrent acute otitis media. Pediatr Infect Dis J. 1997;16:471-478.
27. Arrieta A, Arguedas A, Fernandez P, et al. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. Antimicrob Agents Chemother. 2003;47:3179-3186.
28. Dagan R. Treatment of acute otitis media: challenges in the era of antibiotic resistance. Vaccine. 2001;19:S9-S16.
29. Dagan R, Leibovitz E, Piglansky L, Yagupsky P. Effect of antibiotic treatment on pneumococcal nasopharyngeal carriage (Pnc-car) during and after acute otitis media (AOM): comparison of three oral drugs [Abstract 1028]. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26 to 29, 1999.
30. Dagan R, Leibovitz E, Cheletz G, Leiberman A, Porat N. Antibiotic treatment in acute otitis media promotes superinfection with resistant Streptococcus pneumoniae carried before initiation of treatment. J Infect Dis. 2001;183:880-886.
31. Dagan R, Piglansky L, Greenberg D, et al. Dynamics of nasopharyngeal pneumococcal carriage (NP-Pnc-car) in children with recurrent and non-responsive acute otitis media (RNR-AOM) [Abstract G-1825]. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 16 to 19, 2001.
32. Dagan R, Leibovitz E, Leiberman A, Yagupsky P. Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms. Pediatr Infect Dis J. 2000;19:S57-S65.
33. Jones RN, Mutnick AH, Varnam DJ. Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS MI00-S12) on the susceptibility patterns of five parenteral cephalosporins: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). J Clin Microbiol. 2002;40:4332-4333.
34. Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J. 2000;19:1040-1045.
35. Jones RN, Pfaller MA. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis. 2000;31(suppl 2):S16-S23.
36. Fung-Tomc J, Minassian B, Kokek B, et al. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother. 2000;45:437-446.
37. Boswell FJ, Andrews J, Jevons G, Wise R. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother. 2002;50:495-502.
38. Nagai K, Davies TA, Dewasse BE, et al. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin, and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother. 2001;48:365-374.
39. Schmitz F-J, Boos M, Mayer S, et al. Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae [letter]. Antimicrob Agents Chemother. 2001;45:2666-2667.
40. Gotfried M, Quinn TC, Gothelf S, et al. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study. Diagn Microbiol Infect Dis. 2002;44:85-91.
41. Anzueto A, Gotfried M, Wikler MA, Russo R, Nicholson SC. Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis. Clin Ther. 2002;24:906-917.
42. Sher LD, Poole MD, von Seggern K, et al. Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. Otolaryngol Head Neck Surg. 2002;127:182-189.
43. Arguedas A, Sher L, Lopez E, et al. Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. Pediatr Infect Dis J. 2003;22:949-955.
44. Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. Pediatr Infect Dis J. 2003;22:943-949.
45. Jones RN, Pfaller MA. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999). J Clin Microbiol. 2000;38:4298-4299.
46. Chen DK, McGeer A, de Azavedo JC, Low DE, Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233-239.
47. Zheng X, Johnson C, Lu Y, et al. Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes. Int J Antimicrob Agents. 2001;18:373-378.
48. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:747-750.
49. Sader HS, Jones RN, Silva JB, SENTRY Participants Group (Latin America). Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagn Microbiol Infect Dis. 2002;44:281-288.
50. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:1405-1433.
51. Centers for Disease Control and Prevention. Resistance of Streptococcus pneumoniae to fluoroquinolones: United States, 1995-1999. MMWR. 2001;50:800-804.
52. Mandell LA, Peterson LR, Wise R, et al. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis. 2002;35:721-727.
53. Stahlmann R, Lode H. Safety overview: toxicity, adverse effects, and drug interactions. In: Andriole VT, ed. The Quinolones. 3rd ed. San Diego, CA: Academic Press; 2000:397-453.
54. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis. 1997;25:1196-1204.
55. Schaad UB. Use of the quinolones in pediatrics. In: Andriole VT, ed. The Quinolones. 3rd ed. San Diego, CA: Academic Press; 2000:455-475.
56. Schaad UB, Abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J. 1995;14:1-9.
57. Schaad UB, Sander E, Wedgwood J, Schaffner T. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect Dis J. 1992;11:1047-1049.
58. Schaad UB, Stoupis C, Wedgwood J, Tschaeppeler H, Vock P. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J. 1991;10:723-729.
59. Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J. 2002;21:525-529.
60. National Committee for Clinical Laboratory Standards. MIC testing supplemental tables (M 100-S10). Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.